Preparations containing ceraracertib

A ceraracertib formulation with dibasic calcium phosphate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and magnesium stearate addresses compliance and manufacturability issues, enhancing stability and uniform drug release for effective cancer therapy.

JP7873676B2Active Publication Date: 2026-06-12ASTRAZENECA AB

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
ASTRAZENECA AB
Filing Date
2022-03-21
Publication Date
2026-06-12

Smart Images

  • Figure 0007873676000007
    Figure 0007873676000007
  • Figure 0007873676000008
    Figure 0007873676000008
  • Figure 0007873676000009
    Figure 0007873676000009
Patent Text Reader

Abstract

A pharmaceutical formulation is described that includes selarasertib, dibasic calcium phosphate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate.
Need to check novelty before this filing date? Find Prior Art